A study of patient preference between ODM-201 and Enzalutamide in men with metastatic castrate-resistant prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Darolutamide (Primary) ; Enzalutamide
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms ODENZA Preference
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 25 Oct 2017 New trial record